Guided Therapeutics Financials
| GTHP Stock | USD 0.19 0.03 18.75% |
With this module, you can analyze Guided financials for your investing period. You should be able to track the changes in Guided Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Guided |
Understanding current and past Guided Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Guided Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Guided Therapeutics' assets may result in an increase in income on the income statement.
The data published in Guided Therapeutics' official financial statements typically reflect Guided Therapeutics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Guided Therapeutics' quantitative information. For example, before you start analyzing numbers published by Guided accountants, it's essential to understand Guided Therapeutics' liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Guided Therapeutics Stock Summary
Guided Therapeutics competes with Nephros, Intelgenx Technologs, and SANUWAVE Health. Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia. Guided Therapeutics operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 5 people.| Instrument | USA OTC Stock View All |
| Exchange | OTCQB Exchange |
| Business Address | 5835 Peachtree Corners |
| Sector | Healthcare |
| Industry | Medical Devices |
| Benchmark | Dow Jones Industrial |
| Website | www.guidedinc.com |
| Phone | 770 242 8723 |
| Currency | USD - US Dollar |
Guided Therapeutics Key Financial Ratios
Guided Therapeutics' financial ratios allow both analysts and investors to convert raw data from Guided Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Guided Therapeutics over time and compare it to other companies across industries.| Return On Asset | -0.63 | |||
| Beta | 0.67 | |||
| Z Score | -84.2 |
Guided Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Guided Therapeutics's current stock value. Our valuation model uses many indicators to compare Guided Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Guided Therapeutics competition to find correlations between indicators driving Guided Therapeutics's intrinsic value. More Info.Guided Therapeutics is one of the top stocks in return on asset category among its peers. It also is one of the top stocks in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Guided Therapeutics' earnings, one of the primary drivers of an investment's value.Guided Therapeutics Systematic Risk
Guided Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Guided Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Guided Therapeutics correlated with the market. If Beta is less than 0 Guided Therapeutics generally moves in the opposite direction as compared to the market. If Guided Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Guided Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Guided Therapeutics is generally in the same direction as the market. If Beta > 1 Guided Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Guided Therapeutics November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Guided Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Guided Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Guided Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Guided OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Guided Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 19.91 | |||
| Information Ratio | 0.1128 | |||
| Maximum Drawdown | 70.0 | |||
| Value At Risk | (20.00) | |||
| Potential Upside | 26.67 |
Additional Tools for Guided OTC Stock Analysis
When running Guided Therapeutics' price analysis, check to measure Guided Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guided Therapeutics is operating at the current time. Most of Guided Therapeutics' value examination focuses on studying past and present price action to predict the probability of Guided Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guided Therapeutics' price. Additionally, you may evaluate how the addition of Guided Therapeutics to your portfolios can decrease your overall portfolio volatility.